Evidence map›Paper›PMID 33776703›Full record

ArticleCase reports in oncology

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.

Go Makimoto, Keita Kawakado, Masamoto Nakanishi, Tomoki Tamura, Shoichi Kuyama

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Go MakimotoDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Keita KawakadoDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Masamoto NakanishiDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Tomoki TamuraDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Shoichi KuyamaDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Iwakuni Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alectinib is a key drug for treating

Indexed as

AlectinibAnaplastic lymphoma kinaseHepatotoxicityLorlatinibNon-small-cell lung cancer

Identifiers

PMID33776703
PMCPMC7983536
OpenAlexW3139334892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.